Navigation Links
New vaccine means bye-bye to bacteria in the lung

Pseudomonas aeruginosa is a bacterium that can cause respiratory tract infections, which can be life threatening in patients who have cystic fibrosis. It is therefore important to develop a vaccine against this pathogen. Appearing online on 1 April 2005 in advance of print publication of the May issue of The Journal of Clinical Investigation, Ronald Crystal and colleagues from Cornell University use a novel strategy to create a genetic vaccine against P. aeruginosa.

The researchers use a modified adenovirus vector vaccine expressing a region of the outer membrane of P. aeruginosa, called OprF, which had previously been recognized as a promising vaccine candidate. This region of the bacteria was expressed in the capsid area of the vector. Immunization of mice with this vaccine induced antibody production and protected the mice from exposure to a deadly dose of the bacteria. Importantly, the mice could be repeatedly given the vaccine and the immune response against P. aeruginosa was boosted. Usually, adenovirus vectors do not allow for repeated infection.

These results may be useful in the development of vaccines against bacterial pathogens. The findings that a vaccine against Pseudomonas aeruginosa is therapeutic in mice offers promise for patients with cystic fibrosis or other disorders that prevent them from effectively fighting off respiratory tract infections.


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that it ... insights to support its reporting, help direct future campaigns, and share ... charity will be using Brandwatch Analytics social listening and analytics technology ... the topics and issues that are a priority for its supporters. ... "Until recently we,ve ...
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... ... of biologics. To acquire information on the desired increase and/or decrease in antibody-dependent ... industry for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Functional near-infrared spectroscopy ... is being explored as a way to track the brain’s response to acute pain ... activation by cold pressor test ,” published today in the journal Neurophotonics , ...
(Date:3/22/2017)... MARLBOROUGH, Mass. , March 22, 2017 /PRNewswire/ ... company developing innovative therapeutics that address significant unmet ... PhD, RXi,s Chief Business Officer, will present at ... The forum will provide a platform to present ... research institutes, leading pharmaceutical and biotech companies as ...
(Date:3/20/2017)... ... 20, 2017 , ... Avexegen Therapeutics Inc., an innovative biotechnology ... entered into an exclusive global license agreement with Children’s Hospital Los Angeles (CHLA) ... orphan disease) as well as Crohn’s Disease and Ulcerative Colitis. , ...
Breaking Biology Technology: